Status:
TERMINATED
Renal Graft Function After Treatment With Erythropoietin (EPO)
Lead Sponsor:
University Hospital, Limoges
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Ischemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Background : Numerous studies have outlined the cellular pleiotropic effects of erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as after acute ischemic injury...
Detailed Description
Abstract : Since the discovery that EPO and its receptor are expressed in various tissues, numerous studies have demonstrated that EPO is not only involved in erythropoiesis but also exerts pleiotropi...
Eligibility Criteria
Inclusion
- donor:
- cadaveric organ donor,
- age ≥ 18 years,
- mono-organ (kidney) retrieval,
- retrieval done in the centres of Limoges, Bordeaux, Toulouse, Angers, Brest, Nantes, Poitiers, Rennes, Tours,
- hematocrit ≤ 45%.
- Recipient:
- age ≥ 18 years,
- on the waiting list for a kidney graft.
Exclusion
- living donors,
- age under 18 years,
- multi-organ retrieval,
- donor hematocrit above 45%
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01450878
Start Date
December 1 2011
End Date
March 1 2013
Last Update
September 5 2016
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Néphrologie
Angers, France, 49000
2
CHU d'ANGERS - CHPOT
Angers, France, 49933
3
CHU de BORDEAUX - CHPOT
Bordeaux, France, 33076
4
CHU de BORDEAUX - Service de Néphrologie
Bordeaux, France, 33076